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Abstract
Introduction: Non-specific abnormalities in liver function tests might accompany the clinical
course of hyperthyroidism. Hyperthyroidism can cause the elevation of hepatic enzymes and
bilirubin. Jaundice is rare in overt hyperthyroidism, especially in subclinical hyperthyroidism. On the
other hand, the use of anti-thyroid drugs has rarely been associated with toxic hepatitis and
cholestatic jaundice.
Case presentation: Here we present two cases of cholestasis that accompanied two distinct
forms of clinical hyperthyroidism. The first patient had a clinical presentation of severe cholestasis
in the absence of congestive failure related to hyperthyroidism. The second case had developed
intrahepatic cholestasis in the presence of subclinical hyperthyroidism, and improved with
rifampicin treatment.
Conclusion: Hyperthyroidism should be a consideration in non-specific liver dysfunction.
Introduction
Liver function test abnormalities accompanying thyroid
diseases are rarely reported. Changes in liver enzyme lev-
els can be non-specific in nature or of a cholestatic profile.
In recent years, there have been rapid developments in the
understanding pertaining to the pathophysiology of
cholestasis secondary to thyroid disease and cholestatic
injury. The mechanism underlying the hepatic damage
observed in hyperthyroidism is not clear; however, since
the beginning of the 20th century, different functional
and histological hepatic changes have been reported in
patients with thyrotoxicosis. In roughly half of hypothy-
roidism cases, liver function tests were found to be abnor-
mal, whereas liver histology was normal [1,2]. In
hyperthyroidism, liver function tests might reveal non-
specific elevations of the transaminases, mild indirect
hyperbilirubinemia (30% of cases), alkaline phosphatase
(ALP) elevations (40% of patients), and there may be
minor changes in liver histology. Liver enzyme elevations
in thyroid disease might be paradoxically related to pro-
pylthiouracil (PTU) therapy [1-3].
We present two cases of intrahepatic cholestasis develop-
ing in thyrotoxicosis by different mechanisms, and
improvement via different treatment regimens. Our aim is
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to remind physicians of hyperthyroidism and anti-thyroid
medications in the differential diagnosis of cholestasis.
Case presentation
Case 1
A mass was detected on the left adrenal gland of a 47-year-
old male patient who was under investigation for com-
plaints of fatigue, loss of appetite and weight loss (20 kg)
present for the previous three months. The subsequent
fine-needle aspiration biopsy diagnosed a myelolipoma.
During these investigations, the patient developed jaun-
dice and pruritus, and was referred to the gastroenterology
clinic for the differential diagnosis of cholestasis.
The patient had no history of chronic disease, smoking,
pharmaceutical or herbal medications, infections, abuse
of alcohol, blood transfusion or traveling. On initial
examination, there was significant jaundice, the skin was
moist and the hands were tremulous. He had tachycardia.
There were no signs of thyroid ophthalmopathy. The thy-
roid gland was non-palpable and there were no findings
of heart failure, chronic liver disease or infection. His lab-
oratory tests showed a total bilirubin value of 15 mg/dl
(normal range (N): 0.2–1.3), direct bilirubin 11 mg/dl
(N: 0.1–0.5), alkaline phosphatase (ALP) 393 IU/l (N:
40–150), alanine aminotransferase (ALT) 46 IU/l (N: 0–
55), aspartate aminotransferase (AST) 46 IU/l (N: 5–34),
γ-glutamyl transferase (GGT) 34 IU/l (N: 9–64), lactate
dehydrogenase (LDH) 399 IU/l (N: 125–243), calcium
(Ca) 9.7 mg/dl (N: 8.4–10.2), phosphorus (P) 2.3–4.7
mg/dl, hemoglobin 12.5 g/dl, prothrombin time 10 sec-
onds and α-fetoprotein (α-FP) and carcino-embryonic
antigen (CEA) were within normal limits. Peripheral
blood was negative for the antibody to hepatitis B surface
antigen (HBsAg), immunoglobulin M antibody (IgM) to
hepatitis B core antigen (anti-HBc), IgM antibody to hep-
atitis A virus (IgM anti-HAV), hepatitis C virus (HCV),
human immunodeficiency virus (HIV), syphilis (VDRL),
cytomegalovirus (CMV), Epstein-Barr virus (EBV), bru-
cella and autoantibodies (ANA, AMA, ASMA and LKM1).
Abdominal ultrasonography (USG) findings were normal
except for leveling sludge in the gall bladder and the adre-
nal mass. An abdominal magnetic resonance imaging
(MRI) scan revealed an adrenal mass measuring 6 × 8 × 6
cm with lobulated contours and well-defined borders; the
mass was iso-intense with the retroperitoneal adipose tis-
sue. Magnetic resonance cholangiography findings were
normal. With a preliminary diagnosis of intrahepatic
cholestasis, thyroid function tests were ordered and a liver
biopsy was planned. Serum thyroid hormone levels were
free triiodothyronine (FT3) 10.2 ng/dl (N: 1.8–4.2), free
thyroxine (FT4) 5.27 ng/dl (N: 0.8–1.9), thyroid-stimulat-
ing hormone (TSH) less than 0.02 mU/ml (N: 0.4–4) and
anti-thyroid peroxidase 283 (N: 0–35). In the thyroid
USG, parenchymal echogenicities of both thyroid lobes
were heterogeneous. Thyroid scintigraphy (3 mCi Tc 99 m
pertechnetate IV) results were consistent with a diffuse
hyperplasic thyroid gland that demonstrated diffuse and
high-level technetium uptake. The patient was diagnosed
with Graves' disease. Histopathological findings from a
liver biopsy specimen were found to be consistent with
acute cholestasis (cannalicular cholestasis). We consid-
ered that cholestatic jaundice had developed secondary to
hyperthyroidism. PTU therapy was initiated at a daily
dose of 300 mg in three divided doses. On the sixth day of
PTU therapy, the patient developed pruritus together with
elevations in cholestatic enzymes and bilirubin (total
bilirubin: 37 mg/dl; conjugated bilirubin: 24 mg/dl),
necessitating the cessation of anti-thyroid treatment.
Radioactive iodine (I131) was administered for thyroid
ablation. During follow-up, initially LDH, then total
bilirubin, and lastly ALP levels gradually returned to nor-
mal values. Weekly ALP measurements during the first 45
days were 393, 409, 362, 284, 272 and 190 IU/l. Subse-
quent tests showed ALP levels of 162 IU/l at month 2 and
148 IU/l at month 3. Within three months, all biochemi-
cal tests were within normal limits.
Case 2
A 67-year-old female patient was admitted to hospital
with complaints of pruritus and jaundice. She had no his-
tory of liver disease, and had been diagnosed with hyper-
thyroidism three years previously. The patient had been
on anti-thyroid medications for one year, and had not
experienced any hepatic problems during this period.
Anti-thyroid drug therapy had been discontinued two
years previously because she had reached normal thyroid
status both clinically and on laboratory tests. In her labo-
ratory results two months previously, serum thyrotropin
levels were suppressed (TSH less than 0.01 uIU/ml (N:
0.4–4)), and free thyroxine was within normal limits (FT4
1.15 ng/dl (N: 0.9–1.7)). Our assessment was that the
patient had subclinical hyperthyroidism. Six weeks prior
to her admission to our clinic, she had developed pruritus;
she had no history of other pharmaceutical or herbal
medication use, infections, abuse of alcohol or contact
with toxic substances. Physical examination findings were
normal except for jaundice and the skin manifestations of
pruritus. At the time of admission, her laboratory results
were: AST 38 IU/l (N: 5–34), ALT 41 IU/l (N: 0–55), GGT
203 IU/l (N: 9–64), ALP 358 IU/l (N: 40–150), LDH 182
IU/l (N: 125–243), total bilirubin 24.5 mg/dl (N: 0.2–
1.3), direct bilirubin 17.5 mg/dl (N: 0.1–0.5), Ca 8.8 mg/
dl (N: 8.4–10.2) and P 2.3–4.7 mg/dl. Markers of viral
hepatitis (HBsAg, anti-HBc IgM, anti-HAV IgM, HCV,
HIV, VDRL, CMV, EBV), brucella and autoimmune hepa-
titis (ANA, AMA, ASMA and LKM1) were all negative.
Endoscopic retrograde cholangiopancreatography (ERCP)
and other imaging techniques did not reveal any pathol-
ogy. Follow-up thyroid hormone levels were FT3 3.8 ng/dl,Journal of Medical Case Reports 2008, 2:116 http://www.jmedicalcasereports.com/content/2/1/116
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FT4 1.34 ng/dl (N: 1.8–4.2) and TSH 0.08 uIU/ml, corre-
lating with subclinical hyperthyroidism. The patient's
serum was negative for thyroid autoantibodies. Thyroid
USG revealed a multinodular goiter pattern. The thyroid
biopsy revealed nodular hyperplasia. Liver biopsy results
showed degeneration and regeneration of hepatocytes,
pigment accumulation in the cytoplasm of some hepato-
cytes, dilatation of the sinusoids, bile plugs, a slight
increase in Kupffer cells, rare mononuclear inflammatory
cells and regular appearance of bile ductules. This was
consistent with intrahepatic cholestasis (Figure 1).
The symptoms of jaundice and pruritus did not respond
to an 18-day course of treatment with corticosteroids,
ursodeoxycholic acid or other symptomatic treatment. We
added rifampicin at a dose of 600 mg/day. On the third
day of rifampicin therapy, cholestasis parameters started
to regress and were significantly improved by day 10.
Weekly measurements during rifampicin use revealed ALP
levels of 358, 349, 241 and 166 IU/l, and at month 2 ALP
levels had declined to 103 IU/l. In the second month of
therapy, clinical and cholestasis-related laboratory find-
ings were within normal limits. The patient was not
placed under specific treatment due to the subclinical
course of the disease, but frequent follow-up of thyroid
function tests were recommended.
Discussion
The first patient had presented with cholestasis secondary
to autoimmune hyperthyroidism, and his jaundice was
aggravated by anti-thyroid medications. He was treated
with radioactive iodine (I131), and the jaundice improved
when euthyroidism was achieved after three months. In
the second patient, cholestatic jaundice was caused by
subclinical hyperthyroidism and treated with rifampicin.
However, rifampicin use can also cause intrahepatic
cholestasis [3]. The issues raised by these cases include the
etiology of liver enzyme abnormalities, the elevation of
serum bilirubin levels in hyperthyroidism and the clinical
management of these liver abnormalities.
The liver is the primary organ of thyroid hormone metab-
olism. This partly explains the complexity of the influ-
ences of increased thyroid hormone levels on liver
function tests. Individual differences are attributed to liver
enzyme levels [4].
The co-occurrence of hyperthyroidism and abnormal liver
function tests is rare and the mechanism underlying
hepatic dysfunction is not well known. In etiology,
enzyme induction and the role of venous congestion due
to heart failure are stipulated. Hypoxia is blamed as
another mechanism and it is anticipated that increased
oxygen utilization cannot be totally compensated for by
hepatic blood flow. In patients with high levels of T3 and
T4, relatively severe hypoxemia develops and the pericen-
tral parts of hepatic acini become prone to damage. The
mechanism underlying hyperbilirubinemia is not well
known either and there are no available data supporting
the direct toxic effects of thyroid hormones on the liver
[5].
Cholestasis secondary to medication and chemical agents
is on the rise for liver diseases [1]. With such feedback,
there has been a rapid advance in information pertaining
to the pathophysiology of cholestasis and the mechanism
of cholestatic damage. Injury to hepatocytes and distur-
bances in the secretion and flow of bile has been blamed
in cholestasis secondary to medications. Anti-thyroid
medications are listed among pharmacological agents
that cause cholestasis [6]. In our first case, parameters of
cholestasis had amplified further with the initiation of
PTU therapy and ceased to intensify upon discontinua-
tion. This pattern was associated with the cholestatic effect
of PTU.
Liver pathologies ranging from mild to fulminant liver
failure with a fatal course have been reported with PTU
use [7]. The liver biopsies of three asymptomatic patients
on PTU therapy with ALT elevations were reported as focal
necrosis or ill-defined granuloma composed of foamy his-
tiocytes with ceroid pigment and mild fatty metamorpho-
sis [8]. In both of our patients, signs of intrahepatic
cholestasis existed in their liver biopsies, and pathologies
with an inflammatory process were excluded.
Liver biopsies of five patients [8] with hyperthyroidism
revealed non-specific changes such as mild to moderate
Liver biopsy results consistent with intrahepatic cholestasis Figure 1
Liver biopsy results consistent with intrahepatic 
cholestasis. Hematoxylin and eosin stain, magnification 
×100.Journal of Medical Case Reports 2008, 2:116 http://www.jmedicalcasereports.com/content/2/1/116
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intrahepatic cholestasis, lobular inflammation of eosi-
nophilic origin and Kuppfer cell hyperplasia. There was
no correlation between the severity of histological damage
and thyroid function tests.
Jaundice can be diagnosed during the clinical course of
thyrotoxicosis while mild increases are observed in ALT,
AST and bilirubin levels. In a study by Thompson et al [9],
abnormal function tests and, in particular, elevations of
bilirubin were reported in hyperthyroidism. Despite the
rarity of case presentations of intrahepatic cholestasis
caused by subclinical hyperthyroidism, the condition
might present clinically with findings of severe cholesta-
sis. One report presented a case of severe intrahepatic
cholestasis due to toxic multinodular goiter, with normal
FT3 and FT4 levels, without congestive heart failure, and
with subclinical hyperthyroidism [10]. After the exclusion
of other possible causes of intrahepatic cholestasis, we
concluded that our second case was related to subclinical
hyperthyroidism in the absence of congestive heart fail-
ure.
Although adverse reactions of anti-thyroid medications
are not reported frequently, methimazole (MMI) – and
PTU-related cases have been observed at equal frequencies
[11]. PTU-related hepatocellular and MMI-related choles-
tatic hepatitis cases have been reported [8,12]. The adverse
effects of MMI are related to the dose [11] or of immuno-
logical origin. Side-effects generally appear during the first
three months of treatment, but they may also arise much
later in the course of treatment [7].
In Woeber's review [12], 30 previously published cases of
patients who had developed hepatotoxicity following
treatment with MMI and carbimazole were analyzed; 19
had cholestatic-form clinical presentations. Clinical
improvement is slow, yet the condition is totally reversi-
ble. An analysis of the cases reported by Woeber demon-
strated that advanced age and high-dose anti-thyroid
medications were risk factors for cholestatic damage [12].
In one study, asymptomatic elevations of GGT and ALP
were observed in one-third of patients receiving PTU treat-
ment, and 75.8% were identified as having at least one
biochemical abnormality. AST was elevated in 27.4% of
cases, ALT in 36.8%, ALP in 64.2%, GGT in 16.8% and
bilirubin in 5.3% [13].
In our first case, cholestatic jaundice caused by overt
hyperthyroidism was aggravated as an adverse effect of
PTU. We administered radioactive iodine (I131) for thy-
roid ablation and the patient improved. Thyrotoxic
cholestasis might develop as a result of diverse mecha-
nisms and is corrected with the establishment of euthy-
roidism. Patients should be warned about the side-effects
of medications when anti-thyroid therapy is to be admin-
istered. They should be followed up for hepatotoxicity
and advised to stop treatment if symptoms develop [7].
Treatment can be maintained in patients who do not have
symptoms or hyperbilirubinemia. Anti-thyroid medica-
tion-related pathologies are frequently benign and tran-
sient, and side-effects are reversible in nearly all patients
[7,8].
If intrahepatic cholestasis refractory to other treatments
develops in cases of subclinical hyperthyroidism, patients
may be placed under observation without anti-thyroid
treatment. Rifampicin can be considered as an alternative
treatment choice. It is a pregnane X receptor (PXR) ago-
nist, decreasing the synthesis of bile acids by activating
PXR. PXR is a nuclear receptor predominantly expressed
in the liver and bowel; it coordinates the response of the
liver to environmental toxins. Activated PXR is anti-chole-
static and selective PXR agonists can be used in the treat-
ment of advanced cholestasis. The inhibition of bile acids
with rifampicin can be a protective mechanism for medi-
cation- and bile acid-related cholestasis [14,15]. Owing to
such effects, rifampicin is recommended in cholestasis-
related pruritus at a dose of 300 mg twice daily [3]. The
second case, whose pruritus and jaundice were unrespon-
sive to any symptomatic therapy, showed a rapid response
to treatment with rifampicin.
Conclusion
In non-specific abnormalities of liver function tests,
hyperthyroidism should be considered and the patient's
thyroid function should be assessed.
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